MA55752A - Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies - Google Patents
Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathiesInfo
- Publication number
- MA55752A MA55752A MA055752A MA55752A MA55752A MA 55752 A MA55752 A MA 55752A MA 055752 A MA055752 A MA 055752A MA 55752 A MA55752 A MA 55752A MA 55752 A MA55752 A MA 55752A
- Authority
- MA
- Morocco
- Prior art keywords
- nephropathies
- treatment
- pharmaceutical compositions
- new compounds
- associated pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1905711.6A GB201905711D0 (en) | 2019-04-24 | 2019-04-24 | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55752A true MA55752A (fr) | 2022-03-02 |
Family
ID=66810218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055752A MA55752A (fr) | 2019-04-24 | 2020-04-21 | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220202802A1 (fr) |
| EP (1) | EP3958863B1 (fr) |
| JP (1) | JP2022529814A (fr) |
| KR (1) | KR20220004111A (fr) |
| CN (1) | CN113727711A (fr) |
| AU (1) | AU2020263869A1 (fr) |
| BR (1) | BR112021021117A2 (fr) |
| CA (1) | CA3137445A1 (fr) |
| GB (1) | GB201905711D0 (fr) |
| IL (1) | IL287392A (fr) |
| MA (1) | MA55752A (fr) |
| MX (1) | MX2021012544A (fr) |
| SG (1) | SG11202111739VA (fr) |
| WO (1) | WO2020216740A1 (fr) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7514463B2 (en) * | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
| US8362031B2 (en) * | 2004-08-20 | 2013-01-29 | University Of Kansas | Lonidamine analogues and treatment of polycystic kidney disease |
| CA2769847C (fr) * | 2009-08-10 | 2019-01-08 | The Regents Of The University Of California | Inhibiteurs pyrimido-pyrrolo-quinoxaline dione de la proteine regulatrice de la conductance transmembranaire impliquee dans la fibrose kystique et leurs utilisations |
| TWI633887B (zh) * | 2012-05-31 | 2018-09-01 | 大塚製藥股份有限公司 | 用於預防及／或治療多囊性腎臟病之藥物 |
| WO2016073470A1 (fr) * | 2014-11-04 | 2016-05-12 | The University Of Kansas | Activateurs de l'ampk de lkb1 pour une utilisation thérapeutique dans la polykystose rénale |
| PL3359541T3 (pl) | 2015-10-09 | 2021-01-11 | AbbVie Overseas S.à r.l. | N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA |
| BR112018007165A2 (pt) * | 2015-10-09 | 2019-01-22 | AbbVie S.à.r.l. | novos compostos para tratamento da fibrose cística |
| AU2016333855A1 (en) | 2015-10-09 | 2018-04-26 | AbbVie S.à.r.l. | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use |
| JP2020525446A (ja) * | 2017-06-21 | 2020-08-27 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 常染色体優性多発性嚢胞腎疾患を治療するための嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子 |
-
2019
- 2019-04-24 GB GBGB1905711.6A patent/GB201905711D0/en not_active Ceased
-
2020
- 2020-04-21 BR BR112021021117A patent/BR112021021117A2/pt not_active Application Discontinuation
- 2020-04-21 KR KR1020217038004A patent/KR20220004111A/ko unknown
- 2020-04-21 US US17/605,623 patent/US20220202802A1/en active Pending
- 2020-04-21 SG SG11202111739VA patent/SG11202111739VA/en unknown
- 2020-04-21 JP JP2021562854A patent/JP2022529814A/ja active Pending
- 2020-04-21 WO PCT/EP2020/061083 patent/WO2020216740A1/fr unknown
- 2020-04-21 CA CA3137445A patent/CA3137445A1/fr active Pending
- 2020-04-21 EP EP20721493.3A patent/EP3958863B1/fr active Active
- 2020-04-21 MA MA055752A patent/MA55752A/fr unknown
- 2020-04-21 AU AU2020263869A patent/AU2020263869A1/en not_active Abandoned
- 2020-04-21 CN CN202080030725.9A patent/CN113727711A/zh active Pending
- 2020-04-21 MX MX2021012544A patent/MX2021012544A/es unknown
-
2021
- 2021-10-19 IL IL287392A patent/IL287392A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201905711D0 (en) | 2019-06-05 |
| EP3958863A1 (fr) | 2022-03-02 |
| MX2021012544A (es) | 2021-11-12 |
| SG11202111739VA (en) | 2021-11-29 |
| AU2020263869A1 (en) | 2021-12-23 |
| WO2020216740A1 (fr) | 2020-10-29 |
| EP3958863B1 (fr) | 2024-07-03 |
| JP2022529814A (ja) | 2022-06-24 |
| IL287392A (en) | 2021-12-01 |
| CN113727711A (zh) | 2021-11-30 |
| KR20220004111A (ko) | 2022-01-11 |
| US20220202802A1 (en) | 2022-06-30 |
| CA3137445A1 (fr) | 2020-10-29 |
| BR112021021117A2 (pt) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA51739A (fr) | Compositions pharmaceutiques pour le traitement de la fibrose kystique | |
| MA56019A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA52118A (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| LU92577B1 (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose | |
| MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
| LU92578B1 (fr) | Nouveaux composés et compostions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose | |
| MA50391A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires | |
| MA51916A (fr) | Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide | |
| MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| MA56212A (fr) | Compositions et méthodes de traitement du cancer | |
| MA44737A (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| MA52219A (fr) | Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak | |
| MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| MA50905A (fr) | Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques | |
| MA55143A (fr) | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau | |
| MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
| MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
| MA55497A (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires | |
| MA54792A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| MA45226A (fr) | Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate | |
| MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
| MA52961A (fr) | Compositions et procédés pour la réduction ou le traitement d'une inflammation |